Anirban Goutam Mukherjee¹, Uddesh Ramesh Wanjari²*, Fereshteh Ramezani³, Aishwarya Laxmi⁴, Piyush Jagdish Balgote⁵ and Surbhi Balwant Dhoke²

¹Department of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
²Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India
³Student Research Committee, School of Medicine, Islamic Azad University, Mashhad Branch, Mashhad, Iran
⁴Department of Biotechnology, Institute of science, Banaras Hindu University, Varanasi, Uttar Pradesh, India
⁵Molecular Biology and Genetic Engineering, RTM Nagpur University, Nagpur, Maharashtra, India

*Corresponding Author: Uddesh Ramesh Wanjari, Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India.

Received: July 10, 2021; Published: August 07, 2021

Citation: Mukherjee, A.G., Wanjari, U.R., Ramezani, F., Laxmi, A., Balgote, P.J., and Dhoke, S.B. “Epstein-Barr Virus and its Capacity to Evade the Immune System to Cause Cancer". Acta Scientific Microbiology 4.9 (2021): 52-62.

Abstract

Epstein-Barr virus (EBV) is a commonly known herpes virus that contains tegument, envelope, DNA, and a core with an icosahedral nucleocapsid. Malignant EBV has been implicated in developing Burkitt's lymphoma, lymphoma, nasopharyngeal cancer, Hodgkin's disease, and non-Hodgkin's lymphoma. Gene rearrangements in the immunoglobulin variable region of lymphoma neoplastic cells indicate their origin B-cells in the germinal center. EBV can infect B-cells at all stages and express growth genes. This review focuses on an in-depth idea of how the virus escapes the immune system to cause cancer. Additionally, this work also sheds light on the association of the EVB in various types of cancers like Burkitt's lymphoma, Non-Hodgkin's Lymphoma, and Leiomyosarcomas.

Keywords: Epstein-Barr Virus (EBV); CD 56; miRNA; CDKs; T-cell

Bibliography

1. Ko YH. “EBV and human cancer”. Experimental and Molecular Medicine 1 (2015): e130-e130.
2. Broccolo F., et al. “Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in keratinizing versus non-keratinizing squamous cell carcinoma of the oropharynx”. Infectious Agents and Cancer1 (2018): 1-5.
3. Xiao N., et al. “Regulation and evasion of host immune responses by Epstein-Barr virus”. Wei sheng wu xue bao= Acta Microbiologica Sinica1 (2016): 19-25.
4. Jog NR., et al. “Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model”. Journal of Autoimmunity 106 (2020): 102332.
5. Yun SM., et al. “LMP1 and 2A Induce the Expression of Nrf2 Through Akt Signaling Pathway in Epstein-Barr Virus–Transformed B Cells”. Translational Oncology5 (2019): 775-783.
6. Mawson AR and Majumdar S. “Malaria, Epstein–Barr virus infection and the pathogenesis of Burkitt's lymphoma”. International Journal of Cancer9 (2017): 1849-1855.
7. Gao Y., et al. “IRF4 promotes Epstein–Barr virus activation in Burkitt’s lymphoma cells”. Journal of General Virology5 (2019): 851-862.
8. Yin H., et al. “Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis”. Medical Microbiology and Immunology 5 (2019): 573-583.
9. Montes-Mojarro IA., et al. “Epstein-Barr virus positive T and NK-cell lymphoproliferations: morphological features and differential diagnosis”. Seminars in Diagnostic Pathology1 (2020): 32-46.
10. Agarwal N., et al. “Prognostic Differences: Epstein-Barr Virus–Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases”. World Neurosurgery 99 (2017): 484-490.
11. Dekate J and Chetty R. “Epstein-Barr virus–associated smooth muscle tumor”. Archives of Pathology and Laboratory Medicine7 (2016): 718-722.
12. Qi YF., et al. “EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer”. Virus Research 272 (2019): 197735.
13. Židovec Lepej S., et al. “miRNAs: EBV mechanism for escaping host’s immune response and supporting tumorigenesis”. Pathogens5 (2020): 353.
14. Kang BW., et al. “High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer”. Oncotarget9 (2017): 14988.
15. Sasaki S., et al. “EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions”. Gastric Cancer3 (2019): 486-496.
16. Song Y., et al. “Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer”. Virology 548 (2020): 6-16.
17. Wang M., et al. “The function and therapeutic potential of Epstein-Barr virus-encoded microRNAs in cancer”. Molecular Therapy-Nucleic Acids 17 (2019): 657-668.
18. Wu Y., et al. “EBV‐miR‐BART12 accelerates migration and invasion in EBV‐associated cancer cells by targeting tubulin polymerization‐promoting protein 1”. The FASEB Journal12 (2020): 16205-16223.
19. Song Y., et al. “Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1”. Oncotarget 24 (2013): 36783.
20. Kheir F., et al. “Detection of Epstein-Barr virus infection in non-small cell lung cancer”. Cancers6 (2019): 759.
21. Villarroel-Espindola F., et al. “Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non–small cell lung cancer”. Clinical Cancer Research7 (2018): 1562-1573.
22. Kim SM., et al. “EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells”. Biochemical and Biophysical Research Communications3-4 (2017): 550-555.
23. Shi Q., et al. “Latent membrane protein 2A inhibits expression level of Smad2 through regulating miR‐155‐5p in EBV‐associated gastric cancer cell lines”. Journal of Medical Virology1 (2020): 96-106.
24. Choi SJ., et al. “DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma”. Archives of Pharmacal Research8 (2017): 894-905.
25. Zhang J., et al. “Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis”. Virology Journal1 (2020): 1-8.
26. Zhang J., et al. “Differential expression profiling of lncRNAs related to Epstein‐Barr virus infection in the epithelial cells”. Journal of Medical Virology10 (2019): 1845-1855.
27. Wang H., et al. “The roles of miRNAs and lncRNAs in Epstein-Barr virus associated epithelial cell tumors”. Virus Research (2020): 198217.
28. Wang L., et al. “Effects of ebv‐miR‐BART7 on tumorigenicity, metastasis, and TRAIL sensitivity of non‐small cell lung cancer”. Journal of Cellular Biochemistry6 (2019): 10057-10068.
29. Lee AZE., et al. “Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer”. Oral Oncology 84 (2018): 61-70.
30. Kelly RJ. “Immunotherapy for esophageal and gastric cancer”. American Society of Clinical Oncology Educational Book 37 (2017): 292-300.
31. Png YT., et al. “The Role of NK Cells in EBV Infection and EBV-Associated NPC”. Viruses2 (2021): 300.
32. Pagano JS., et al. “Antiviral drugs for EBV”. Cancers6 (2018): 197.
33. Whitehurst CB., et al. “Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase”. Journal of Virology 9 (2013): 5311-5315.
34. Coen N., et al. “Antiherpesvirus activities of two novel 4′-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases”. Antimicrobial Agents and Chemotherapy 8 (2014): 4328-4340.
35. Farrell PJ. “Epstein–Barr virus and cancer”. Annual Review of Pathology: Mechanisms of Disease 14 (2019): 29-53.
36. Rühl J., et al. “Vaccination against the Epstein–Barr virus”. Cellular and Molecular Life Sciences (2020): 1-10.
37. Perez EM., et al. “Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice”. Oncotarget12 (2017): 19255.
38. van Zyl DG., et al. “Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice”. PLoS Pathogens12 (2018): e1007464.
39. Lao TD., et al. “Molecular screening for Epstein-Barr virus (EBV): detection of genomic EBNA-1, EBNA-2, LMP-1, LMP-2 among Vietnamese patients with nasopharyngeal brush samples”. Asian Pacific Journal of Cancer Prevention: APJCP6 (2017): 1675.
40. Mukherjee AG., et al. “The CRISPR-Cas System as a Technology to Redefine Industrial Biotechnology”. Acta Scientific Microbiology6 (2021): 45-52.
41. Mukherjee AG., et al. “A Review on The Usefulness of Various Eukaryotic Pigments and Metabolites in Cancer Treatment”. WJPR10 (2020): 587-611.
42. Mukherjee AG., et al. “A Review on the Present and Future Aspects of Various Prokaryotic Pigments and Metabolites Demonstrating Anti-Cancerous Properties”. International Journal of Engineering Research and Technology7 (2020): 1262-1266.
43. Ingole AA., et al. “A Review on Carcinogenic Heavy Metals”. International Journal of Engineering Research and Technology3 (2021): 403-411.
44. Mukherjee AG and Wanjari U. “A Short Review on Various Aspects of Gene Sequencing and Metagenomics to Study Human Gut Microbiome”. International Research Journal of Engineering and Technology7 (2020): 1280-1284.

Copyright: © 2021 Mukherjee, A.G., Wanjari, U.R., Ramezani, F., Laxmi, A., Balgote, P.J., and Dhoke, S.B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.